Limbix, a business that develops digital therapies for teenagers, has revealed results from a study of its new SparkRx product. SparkRx is a phone-based self-guided treatment application for teenagers. The trial was published in the American Academy of Pediatrics National conference and exhibition.
Limbix was formed in 2016 and now employs around 30 people, with ambitions to hire another 30 by the second quarter of 2022. The firm has so far secured $9 million in Series A investment, which was completed in May 2020. GSR Ventures led the round, with Sequoia Capital, Storm Ventures, NextGen Venture Partners, and BIXINK Therapeutics joining as existing investors.
Nearly 160 teenagers between the ages of 13 and 22 were randomly selected to use SparkRx or another mental health education app in the research. Each group had mild to severe depressive symptoms, which were assessed using the PHQ-8, a standard depression questionnaire.